Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 181Gastrointestinal 26CNS 21Tumor-Agnostic 14Head & Neck 13Genitourinary 13Gynecologic 10Thoracic 7Other solid neoplasm 7Sarcoma 4Other hematologic neoplasm 1Lymphoid 1Endocrine 1Dermatologic 1

Conditions

Skin Neoplasms 1Melanoma 1

Interventions

pembrolizumab 339Nivolumab 305Ipilimumab 274Cyclophosphamide 195aldesleukin 148Interleukin-2 110fludarabine phosphate 107trametinib 85Temozolomide 83fludarabine 81Dacarbazine 81dabrafenib 77Radiotherapy 75Biopsy 75Vemurafenib 71Imiquimod 53Bevacizumab 51sargramostim 50Magnetic Resonance Spectroscopy 50Specimen Handling 49Radiosurgery 49Peripheral Blood Stem Cell Transplantation 49Paclitaxel 49Aminolevulinic Acid 49binimetinib 48Carboplatin 48Blood Specimen Collection 47cemiplimab 46Cisplatin 453-ingenyl angelate 45

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lapatinib × Dermatologic × Clear all
NCT01264081 2019-11-13

Lapatinib in Stage IV Melanoma With ERBB4 Mutations

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
34 enrolled 11 charts
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡